SCHEMBL8089263

SCHEMBL8089263

Cc1ccc(-c2ccsc2C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.49
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ACHE P22303 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
EDNRB P24530 1/20 0.36
EDNRA P25101 1/20 0.36
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
GAA P10253 2/20 0.35
IDO1 P14902 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
KDM4E B2RXH2 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
PTGS1 P23219 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695291 0.82 PTGS1 (0.51) PTGS2ACHEPTGS1
SCHEMBL1825367 0.81 BCAT2 (0.47) PTGS2ALDH1A1MAPK1HSD17B10EDNRB
SCHEMBL27472057 0.79 PLA2G10 (0.37) PTGS2ALDH1A1TSHRACHEPLA2G10
SCHEMBL28228496 0.79 PTGS2 (0.71) PTGS2PTGS1
SCHEMBL16887409 0.79 PLA2G10 (0.40) PTGS2ALDH1A1MAPTHSD17B10RAB9A
SCHEMBL8038496 0.79 PTGS2 (0.51) PTGS2ALDH1A1MAPTACHEEDNRB
Ammonia Solution, Strong SCHEMBL23908216 0.77 PTGS2 (0.69) PTGS2PTGS1
SCHEMBL2231313 0.77 ALDH1A1 (0.47) PTGS2ALDH1A1MAPTTSHRMAPK1
SCHEMBL2781156 0.77 PTGS2 (0.46) PTGS2ALDH1A1MAPTTSHRMAPK1
SCHEMBL9812737 0.77 MAPK14 (0.50) ALDH1A1MAPTHSD17B10RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063099-B2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-11-22 US disclosed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 EP disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 PTGS2 3248/4885ALDH1A1 747/4885MAPT 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.